Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

Cyclophosphamide 5Etoposide 4Cytarabine 3sargramostim 2denileukin diftitox 2Radiotherapy 2Filgrastim 2Dexamethasone 2Carboplatin 2Amifostine 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1glucarpidase 1etoposide phosphate 1Vincristine 1Silymarin 1Rituximab 1Prednisolone 1Phenobarbital 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Irinotecan 1Ifosfamide 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Fibroblast Growth Factor 7 1Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Silymarin × Lymphoid × Clear all
NCT00055718 2013-12-18

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡